Sanofi Commits Up to $8B to Broaden Regeneron Antibody Alliance
Sanofi has committed up to $8 billion to expand its antibody-development partnership with Regeneron. The renewed agreement centers on next-generation antibody therapeutics.
Topic
Sanofi
Topic
Sanofi
Sanofi Signs New $8 Billion Pact with Regeneron
Sanofi has signed a new $8 billion pact with Regeneron, extending the alliance behind Dupixent and signaling further investment i…
Sanofi Commits $1B to Broaden Regeneron Alliance, Build Next-Gen Dupixent
Sanofi will pay $1 billion to expand its Regeneron alliance and fund a next-generation successor to Dupixent, doubling down on th…
Sanofi and Regeneron Re-Up Alliance as Dupixent Patent Cliff Nears
Sanofi and Regeneron renew their Dupixent alliance ahead of the patent cliff, AstraZeneca commits $2B to Summit, and Lilly report…
Sanofi Pays Regeneron $1B Upfront to Build Next-Gen Dupixent Successors
Sanofi will pay Regeneron $1 billion upfront, plus up to $7 billion in milestones, to co-develop four long-acting antibodies targ…
Regeneron and Sanofi Expand Immunology Partnership in Deal Worth Up to $8 Billion
Regeneron and Sanofi will add next-generation long-acting immunology antibodies to their collaboration in a milestone-based deal…